From Nasdaq: 2024-05-21 02:43:49

AstraZeneca Plc. announced its goal of reaching $80 billion in revenue by 2030, a significant increase from $45.8 billion in 2023. This target will be achieved through growth in oncology, biopharmaceuticals, and rare diseases, along with the launch of 20 new medicines. The company also plans to invest in new technologies for future growth. Additionally, AstraZeneca aims for a mid-30s percentage Core operating margin by 2026, with further growth expected beyond 2026. This strategic commitment to R&D and productivity aims to shape the future of medicine and drive sustained growth.



Read more at Nasdaq: AstraZeneca Targets $80 Bln Revenue By 2030, Plans To Launch 20 New Medicines